Quanterix (NASDAQ:QTRX) Stock Price Up 7.2%

Quanterix Corp (NASDAQ:QTRX) shares rose 7.2% on Friday . The company traded as high as $28.07 and last traded at $27.91, approximately 310,900 shares traded hands during mid-day trading. An increase of 127% from the average daily volume of 136,857 shares. The stock had previously closed at $26.04.

QTRX has been the topic of a number of research reports. ValuEngine cut Quanterix from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Zacks Investment Research cut Quanterix from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. BTIG Research set a $35.00 price target on Quanterix and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Canaccord Genuity restated a “buy” rating and issued a $38.00 price target on shares of Quanterix in a report on Wednesday, July 24th.

The business has a fifty day simple moving average of $30.42 and a 200 day simple moving average of $26.11. The stock has a market cap of $660.33 million, a price-to-earnings ratio of -19.52 and a beta of 1.25. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.91 and a current ratio of 5.43.



Quanterix (NASDAQ:QTRX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). The company had revenue of $13.54 million for the quarter, compared to analyst estimates of $11.40 million. Quanterix had a negative net margin of 78.07% and a negative return on equity of 74.78%. On average, equities research analysts anticipate that Quanterix Corp will post -1.52 EPS for the current fiscal year.

In other Quanterix news, SVP David C. Duffy sold 1,667 shares of the stock in a transaction on Monday, June 17th. The stock was sold at an average price of $32.74, for a total transaction of $54,577.58. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Chairman E Kevin Hrusovsky sold 3,073 shares of the stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $26.00, for a total value of $79,898.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,193 shares of company stock worth $407,257. 30.80% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in QTRX. Ashford Capital Management Inc. acquired a new stake in Quanterix during the 2nd quarter valued at $13,333,000. BlackRock Inc. grew its holdings in Quanterix by 61.2% during the 4th quarter. BlackRock Inc. now owns 660,292 shares of the company’s stock valued at $12,089,000 after buying an additional 250,571 shares during the last quarter. Tikvah Management LLC grew its holdings in Quanterix by 125.0% during the 2nd quarter. Tikvah Management LLC now owns 238,489 shares of the company’s stock valued at $8,059,000 after buying an additional 132,500 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Quanterix by 303.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 159,144 shares of the company’s stock valued at $5,377,000 after buying an additional 119,691 shares during the last quarter. Finally, Allianz Asset Management GmbH grew its holdings in Quanterix by 52.4% during the 2nd quarter. Allianz Asset Management GmbH now owns 316,131 shares of the company’s stock valued at $10,682,000 after buying an additional 108,647 shares during the last quarter. Hedge funds and other institutional investors own 46.27% of the company’s stock.

Quanterix Company Profile (NASDAQ:QTRX)

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

Further Reading: How is a buy-side analyst different from a sell-side analyst?

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.